American Journal of Clinical Pathology · 2019 · 34 citations · 18 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCervical CancerCervical HistopathologyCervical Intraepithelial NeoplasiaCervical PathologyHuman Papillomavirus InfectionOncogenic VirusesCd4+ Tumor-infiltrating LymphocytesCd8+ Tumor-infiltrating LymphocytesCervical Cancer RadiotherapyHigh-risk Human Papillomavirus TypesHuman Papillomavirus PrognosisHuman Papillomavirus StatusImmune Microenvironment AnalysisImmune Microenvironment Prognosis
OBJECTIVES: To evaluate the correlation between tumor-infiltrating lymphocytes (TILs) and the viral load of high-risk human papillomavirus (HR-HPV) in cervical cancer patients. METHODS: A total of 62 cervical cancer patients were recruited during 1993-1994 and assigned into four groups treated with radiotherapy alone or radiotherapy combined with chemotherapy and/or thermotherapy. Ki67+ tumor cells, CD4+, CD8+, FoxP3+, OX40+ and granzyme B+ TILs were detected by immunohistochemistry. The viral load of HR-HPV in biopsy tissues before therapy was detected by in situ hybridization. RESULTS: The patients with high HPV viral load showed a significantly lower 15-year survival rate and an advanced International Federation of Gynecology and Obstetrics (FIGO) stage and increased recurrence rate. The distribution of Ki67+ tumor cells, FoxP3+ TILs, and CD8+/FoxP3+ ratio was obviously different between low and high HPV viral load groups. A worse clinical outcome was also implicated with increased HPV viral load tested by Cox regression analysis. CONCLUSIONS: Patients with increased HR-HPV viral load tend to be resistant to therapy with decreased immune surveillance in the immune microenvironment. Thus, HR-HPV viral load would influence the local immune microenvironment, and then further affect the survival of cervical cancer patients.
18
Matthias Nees, Joel Geoghegan, Tehila Hyman et al. · Journal of Virology · 2001 · 389 citations
FOXP3 Expression and Overall Survival in Breast Cancer
Andrea Merlo, Patrizia Casalini, Maria Luisa Carcangiu et al. · Journal of Clinical Oncology · 2009 · 300 citations
Medicine, Cancer Biology, Oncology +15